Ebenbuild develops patient-specific digital twin technology to illuminate the lung’s internal behavior and support clinical and industrial decisions. By combining advanced physics-based lung models with individual patient data, the company creates virtual replicas that reveal otherwise hidden dynamics and enable safer, more effective interventions.

We pair high-fidelity simulation with practical clinical workflows to predict ventilation outcomes and optimize inhaled drug delivery. Our platform supports simulation of ventilation strategies before application in the ICU and enables in silico trials to improve respiratory drug development.

Target users include critical care teams, respiratory researchers and pharmaceutical developers. Ebenbuild’s goal is to shift pulmonary research and care from heuristic decision-making to precise, simulation-informed treatment planning — maximizing patient benefit and accelerating drug optimization.